BullFrog AI IP is focused on uncovering novel insights for late-stage drug candidates in the pipelines of the leading biopharmaceutical companies of the world. Of particular interest are drug candidates in Phase 3 clinical trials. Our bfLEAPTM platform analyzes such clinical trial data sets to predict which patients will respond to a particular therapy in development, thereby improving inclusion/exclusion criteria and ensuring primary study outcomes are achieved.
bfLEAPTM can identify relationships and correlations from complex data structures to:
- Discover novel drug targets
- Find niche patient populations where a drug candidate is likely to be more effective
- Identify combinations of drugs likely to provide synergistic effects
We use data security protocols designed for highly classified and top-level security clearance programs.